CN101346140A - 含有右旋樟脑磺酸氨氯地平和辛伐他汀的复合制剂及其制备方法 - Google Patents

含有右旋樟脑磺酸氨氯地平和辛伐他汀的复合制剂及其制备方法 Download PDF

Info

Publication number
CN101346140A
CN101346140A CNA2006800492048A CN200680049204A CN101346140A CN 101346140 A CN101346140 A CN 101346140A CN A2006800492048 A CNA2006800492048 A CN A2006800492048A CN 200680049204 A CN200680049204 A CN 200680049204A CN 101346140 A CN101346140 A CN 101346140A
Authority
CN
China
Prior art keywords
amlodipine
weight
compound formulation
simvastatin
rete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800492048A
Other languages
English (en)
Chinese (zh)
Inventor
禹钟守
池文赫
金用镒
李鸿基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Pharmaceutical Co Ltd
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of CN101346140A publication Critical patent/CN101346140A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CNA2006800492048A 2005-12-27 2006-12-22 含有右旋樟脑磺酸氨氯地平和辛伐他汀的复合制剂及其制备方法 Pending CN101346140A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020050130531A KR100742432B1 (ko) 2005-12-27 2005-12-27 암로디핀 캠실레이트 및 심바스타틴을 포함하는 복합제제,및 이의 제조방법
KR1020050130531 2005-12-27

Publications (1)

Publication Number Publication Date
CN101346140A true CN101346140A (zh) 2009-01-14

Family

ID=38218207

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800492048A Pending CN101346140A (zh) 2005-12-27 2006-12-22 含有右旋樟脑磺酸氨氯地平和辛伐他汀的复合制剂及其制备方法

Country Status (11)

Country Link
US (1) US20090005425A1 (enExample)
EP (1) EP1978956A4 (enExample)
JP (1) JP2009521526A (enExample)
KR (1) KR100742432B1 (enExample)
CN (1) CN101346140A (enExample)
AU (1) AU2006330199A1 (enExample)
BR (1) BRPI0620790A2 (enExample)
CA (1) CA2634639A1 (enExample)
IL (1) IL192148A0 (enExample)
RU (1) RU2008130873A (enExample)
WO (1) WO2007075009A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101836981B (zh) * 2009-12-01 2011-12-14 严洁 复方缬沙坦苯磺酸氨氯地平药物组合物及其制备方法
CN105998017A (zh) * 2009-01-23 2016-10-12 韩美科学株式会社 具有提高的稳定性的包含氨氯地平和氯沙坦的固体药物组合物

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010107081A1 (ja) * 2009-03-19 2010-09-23 第一三共株式会社 包装により安定保存された固形製剤
WO2011112993A2 (en) 2010-03-11 2011-09-15 University Of Louisville Research Foundation, Inc. Methods of predicting and decreasing the risk of pregnancy loss
KR20120068277A (ko) * 2010-12-17 2012-06-27 한미사이언스 주식회사 ＨＭＧ－ＣｏＡ 환원효소 억제제 및 아스피린을 포함하는 약제학적 복합제제
BR112014003529A2 (pt) * 2011-08-15 2017-03-14 Technion Res & Dev Foundation combinações de corroles e estatinas
WO2014058046A1 (ja) * 2012-10-12 2014-04-17 味の素株式会社 カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤
KR20200009101A (ko) 2017-10-17 2020-01-29 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 당뇨병을 동반한 심혈관계 질환의 예방 또는 치료용 약학 조성물 및 이를 포함하는 복합제제
KR20190043076A (ko) 2017-10-17 2019-04-25 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 당뇨병을 동반한 심혈관계 질환의 예방 또는 치료용 약학 조성물 및 이를 포함하는 복합제제
KR102306888B1 (ko) 2019-11-25 2021-09-29 성균관대학교산학협력단 구멍쇠미역으로부터 분리된 신규 화합물을 유효성분으로 포함하는 동맥경화 예방 및 치료용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ502283A (en) 1997-08-29 2002-05-31 Pfizer Prod Inc Cardiovascular therapy comprising amlodipine and a statin compound in amounts that are synergistically effective
US20030092745A1 (en) 2000-02-25 2003-05-15 Pfizer Inc. Combination therapy
EP1314425A4 (en) 2000-08-30 2004-06-02 Sankyo Co MEDICINAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE
DE10224612A1 (de) * 2002-06-04 2003-12-24 Lohmann Therapie Syst Lts Wirkstoffhaltige filmförmige Zubereitungen mit verbesserter chemischer Stabilität, und Verfahren zu deren Herstellung
BRPI0407038A (pt) 2003-01-27 2006-01-17 Hanmi Pharm Ind Co Ltd Camsilato de amlodipina amorfo estável, processo para a preparação do mesmo e composição para administração oral deste
US7611728B2 (en) 2003-09-05 2009-11-03 Supernus Pharmaceuticals, Inc. Osmotic delivery of therapeutic compounds by solubility enhancement
WO2006059217A1 (en) * 2004-12-01 2006-06-08 Ranbaxy Laboratories Limited Stable solid dosage forms of amlodipine besylate and processes for their preparation
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105998017A (zh) * 2009-01-23 2016-10-12 韩美科学株式会社 具有提高的稳定性的包含氨氯地平和氯沙坦的固体药物组合物
CN101836981B (zh) * 2009-12-01 2011-12-14 严洁 复方缬沙坦苯磺酸氨氯地平药物组合物及其制备方法

Also Published As

Publication number Publication date
AU2006330199A1 (en) 2007-07-05
US20090005425A1 (en) 2009-01-01
BRPI0620790A2 (pt) 2011-11-22
CA2634639A1 (en) 2007-07-05
RU2008130873A (ru) 2010-02-10
EP1978956A1 (en) 2008-10-15
KR100742432B1 (ko) 2007-07-24
WO2007075009A1 (en) 2007-07-05
KR20070068658A (ko) 2007-07-02
EP1978956A4 (en) 2009-08-19
IL192148A0 (en) 2009-08-03
JP2009521526A (ja) 2009-06-04

Similar Documents

Publication Publication Date Title
JP5660544B2 (ja) 安定性が向上したアムロジピン及びロサルタンを含む固形薬剤的組成物
CN101090718B (zh) 3-羟基-3-甲基戊二酰辅酶a还原酶抑制剂和抗高血压剂的复合剂型及其制备方法
WO2008101723A2 (en) Pharmaceutical composition containing a cholesterol absorption inhibitor
TWI649099B (zh) 包含氨氯地平（ａｍｌｏｄｉｐｉｎｅ）、洛沙坦（ｌｏｓａｒｔａｎ）及羅舒伐他汀（ｒｏｓｕｖａｓｔａｔｉｎ）之藥學組合物配方
EP3360541A1 (en) Pharmaceutical bilayer tablet composition of atorvastatin calcium and ezetimibe
RU2724338C2 (ru) Фармацевтическая комплексная композиция, включающая амлодипин, лозартан и розувастатин
US20110097414A1 (en) Pharmaceutical compositions comprising adsorbate of fenofibrate
JP5988963B2 (ja) ピタバスタチン含有製剤及びその製造方法
CN101346140A (zh) 含有右旋樟脑磺酸氨氯地平和辛伐他汀的复合制剂及其制备方法
US20050239884A1 (en) Compositions comprising hmg-coa reductase inhibitor
CN105431140B (zh) 含有缓释二甲双胍和速释HMG-CoA还原酶抑制剂的复合制剂
JP5235676B2 (ja) （ｅ）−７−〔４−（４−フルオロフェニル）−６−イソプロピル−２−〔メチル（メチルスルホニル）アミノ〕ピリミジン−５−イル〕−（３ｒ，５ｓ）−３，５−ジヒドロキシヘプタ−６−エン酸を含む医薬組成物
KR20120120519A (ko) 나이아신 및 ＨＭＧ－ＣｏＡ 환원 효소 억제제를 포함하는 복합제제 및 그의 제조방법
WO2012013756A2 (fr) Procédé de préparation de comprimés contenant en association la rifampicine, l'isoniazide, la pyrazinamide, et éventuellement l'ethambutol
HK1128413A (en) Complex formulation comprising amlodipine camsylate and simvastatin and method for preparation thereof
CN105163734A (zh) 包含缬沙坦及罗舒伐他汀钙的复合制剂及其制造方法
CN103641764B (zh) 调节血脂的药物组合物
US20190070167A1 (en) Pitavastatin containing preparation and method for producing same
MX2008007383A (en) Complex formulation comprising amlodipine camsylate and simvastatin and method for preparation thereof
FR2963236A1 (fr) Procede de preparation d'une composition pharmaceutique contenant en association la rifampicine, l'isoniazide, la pyrazinamide, et eventuellement l'ethambutol
KR20090048023A (ko) 암로디핀 베실레이트와 아토르바스타틴 칼슘을 함유하는경구용 복합제제
TW201028150A (en) Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
OA16317A (fr) Procédé de préparation de comprimés contenant en association la rifampicine, l'isoniazide, la pyrazinamide et éventuellement l'éthambutol.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1128413

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090114

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1128413

Country of ref document: HK